The Netherlands facility is designed to handle a wide range of nanomedicines, including lipid-based nanoparticles ...

Osivax, a biopharmaceutical company developing vaccines for broad-spectrum protection against infectious viruses, has ...

First patient dosed in phase 1b trial of MB310 therapy Microbiotica, a clinical-stage biopharma company, has announced the dosing of the first patient in its Phase 1b First-in-Human trial, COMPOSER-1, ...

A new scientific trial evaluating Bavarian Nordic’s mpox vaccine in pregnant and breastfeeding women and infants is set to launch in the Democratic Republic of Congo (DRC). This research could expand ...

The Scottish Medicines Consortium (SMC) has approved Kite’s CAR T-cell therapy, Yescarta (axi-cel), for treating adult patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell ...

Peace out When Bob Marley sang about ‘so much trouble in t ...

Our job, if we still have one, is to unravel what it is, why it is and, gulp, who (if anyone) it is! While we reflect on civilisation’s future, let’s look in the rear-view mirror of the driverless car ...

Arcellx Inc, a biotechnology firm focused on cell therapy innovations, has announced impressive results from its studies on ...

Valneva Scotland has partnered with Team Jak, a West Lothian-headquartered charity focused on supporting children and young people with cancer. The Livingston-based vaccine producer will provide ...

Alexion, AstraZeneca Rare Disease, announced that the National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Voydeya (danicopan). This first-in-class, oral ...

New treatment option for patients with newly diagnosed multiple myeloma The European Commission has approved the subcutaneous (SC) formulation of DARZALEX (daratumumab) in combination with bortezomib, ...

The National Institute for Health and Care Excellence (NICE) has announced that people with heart failure can now stay healthier remotely through advanced remote monitoring technology designed to ...